Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies

--News Direct--

Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the exclusive license of potential monoclonal antibodies from Curia Global, a leading contract research, development and manufacturing organization.

Lederman said Tonix has obtained an exclusive license for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection.

Proactive Studio

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tonix-pharmaceuticals-discusses-exclusive-license-of-potential-monoclonal-antibodies-232354037